Harpreet Singh: New Era for ADCs in HER-2 + Metastatic Breast Cancer
Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn:
“Antibody-drug conjugates (ADCs) are poised to reshape the oncology landscape and are ushering in a new era for HER-2 positive metastatic breast cancer.
At ASCO 2025, the phase 3 DESTINY-Breast09 trial showed fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab achieved a median progression-free survival of 40.7 months vs 26.9 months with the long-standing CLEOPATRA regimen (THP), a 13.8-month improvement that could redefine the first-line standard of care.
“Given the near doubling of the duration of disease control…there are plans to engage with health authorities and follow the process for regulatory approval. This would represent a paradigm shift, as THP has been a standard therapy approach for over a decade,” Sara M. Tolaney, MD, stated during her presentation at ASCO 2025.
Backed by these results, last month the FDA granted Breakthrough Therapy Designation for this first-line combination. The implications extend beyond this single trial, toward a future where potent targeted therapies are used earlier, more effectively, and with the potential to further improve long-term outcomes.”
More posts Featuring Harpreet Singh in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023